Biodexa Pharmaceuticals (BDRX) announced the promotion of Fiona Sharp to CFO and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistently broadened her remit to include many of the responsibilities of a CFO. Stephen Stamp will relinquish his roles as CFO and Company Secretary but remain as CEO.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals Prices $10 Million U.S. Public Offering to Fund Pipeline
- Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering
- Biodexa Pharmaceuticals PLC-ADR trading resumes
- Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause
- Biodexa announces enrollment of first European patients in Phase 3 Serenta trial